Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Juan P. Frias, Srikanth Deenadayalan, Lars Erichsen, Filip K. Knop, Ildiko Lingvay, Stanislava Macura, Chantal Mathieu, Sue D. Pedersen, Melanie Davies

Research output: Contribution to journal › Article › peer-review